PREDILIFE Receives Updated Stock Analysis from In Extenso Finance

PREDILIFE, a French company specializing in artificial intelligence for predicting medical risks, announced a new stock target price from In Extenso Finance on May 1, 2024. In Extenso, focusing primarily on small to mid-sized growing companies, has set the price target at €25.07, indicating a 391% potential increase from the previous close of €5.10 on April 29, 2024.

The positive outlook is part of an annual review conducted by the investment bank. Predilife noted the valuation reflects ongoing enhancements to its intellectual property, including the MammoRisk® test, which features in the European MyPeBS study.